KAPVAY Drug Patent Profile
✉ Email this page to a colleague
When do Kapvay patents expire, and what generic alternatives are available?
Kapvay is a drug marketed by Concordia Pharms Inc and is included in one NDA.
The generic ingredient in KAPVAY is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kapvay
A generic version of KAPVAY was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KAPVAY?
- What are the global sales for KAPVAY?
- What is Average Wholesale Price for KAPVAY?
Summary for KAPVAY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,871 |
| Drug Prices: | Drug price information for KAPVAY |
| What excipients (inactive ingredients) are in KAPVAY? | KAPVAY excipients list |
| DailyMed Link: | KAPVAY at DailyMed |
Recent Clinical Trials for KAPVAY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Arthroplasty Foundation, Inc. | Phase 4 |
| University of Louisville | Phase 4 |
| Mihaela Visoiu | N/A |
Paragraph IV (Patent) Challenges for KAPVAY
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| KAPVAY | Extended-release Tablets | clonidine hydrochloride | 0.1 mg and 0.2 mg | 022331 | 1 | 2011-03-04 |
US Patents and Regulatory Information for KAPVAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-003 | Sep 28, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-004 | Sep 28, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for KAPVAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-003 | Sep 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Concordia Pharms Inc | KAPVAY | clonidine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022331-004 | Sep 28, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for KAPVAY
See the table below for patents covering KAPVAY around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
